More than a dozen studies of Ocrevus for multiple sclerosis presented at ECTRIMS.
These data include abstracts highlighting new longer-term efficacy and safety for Ocrevus as well as ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS.
Ocrevus data also shows sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS). In addition, long-term safety analysis of all clinical trials will reinforce the consistently favorable benefit-risk profile of Ocrevus. A subgroup analysis of three studies (SaROD, CHORDS and ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2-hour Ocrevus infusion will be presented.
Abstracts include: "Sustained Reduction in 48-week Confirmed Disability Progression in Patients with PPMS Treated with Ocrelizumab in the ORATORIO OLE: 8-Year Follow-up", "Long-term Reduction of Relapse Rate and Confirmed Disability Progression After 7.5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis in the OPERA OLE" and "Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis".
Related news and insights
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment.
Merck KGaA, a leading science and technology company, shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the oral, central nervous system (CNS)-penetrant, fully covalent Bruton’s tyrosine kinase inhibitor (BTKi) evobrutinib impacted brain lesions associated with chronic inflammation in the CNS, making it the first BTKi to show significant reductions in slowly expanding lesions (SEL).
Novartis announced data demonstrating the safety of Kesimpta (ofatumumab) over extended exposure (about 3.5 years) in patients with relapsing forms of multiple sclerosis (RMS). LITHIOS Phase IIIb open-label extension study data based on about 3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there was no apparent association between IgG levels and the risk of serious infections.